Association of eNOS Glu298Asp polymorphism with end-stage renal disease

Hypertension

Volumn 40, Issue 4, 2002, Pages 535-540

  Noiri, Eisei ^a   Satoh, Hiroaki ^a   Taguchi, Jun Ichi ^b   Brodsky, Sergey V ^c   Nakao, Akihide ^a   Ogawa, Yumiko ^d   Nishijima, Satomi ^d   Yokomizo, Takehiko ^a   Tokunaga, Katsushi ^a   Fujita, Toshiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKAI UNIVERSITY   (Japan)

^c STONY BROOK UNIVERSITY   (United States)

^d ASTELLAS PHARMA INC   (Japan)

Author keywords

Diabetes mellitus; Nitric oxide synthase; Polymerase chain reaction; Polymorphism

Indexed keywords

ASPARTIC ACID; CALCIMYCIN; GLUTAMIC ACID; GLYCINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; THREONINE;

ADULT; AGED; ANIMAL CELL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHO CELL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA POLYMORPHISM; ELECTRODE; ENDOTHELIUM; EXON; FEMALE; FLUOROMETRY; GENE OVEREXPRESSION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ANIMALS; CHO CELLS; CRICETINAE; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSFECTION;

EID: 0036791822     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000033974.57407.82     Document Type: Article

References (28)

1. McDonald KK, Zharikov S, Block ER, Kilberg MS. A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the "arginine paradox." J Biol Chem. 1997;272:31213-31216.
2. Sakoda T, Hirata K, Kuroda R, Miki N, Suematsu M, Kawashima S, Yokoyama M. Myristoylation of endothelial cell nitric oxide synthase is important for extracellular release of nitric oxide. Mol Cell Biochem. 1995;152:143-148.
3. Huang PL, Huang Z, Mashimo H, Bloch MA, Moskowitz JA, Bevan MC, Fishman. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995;377:239-242.
4. Hibi K, Ishigami T, Tamura K, Mizushima S, Nyui N, Fujita T, Ochiai H, Kosuge M, Watanabe Y, Yoshii Y, Kihara M, Kimura K, Ishii M, Umemura S. Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction. Hypertension. 1998;32:521-526.
5. Miyamoto Y, Saito Y, Kajiyama N, Yoshimura M, Shimasaki Y, Nakayama M, Kamitani S, Harada M, Ishikawa M, Kuwahara K, Ogawa E, Hamanaka I, Takahashi N, Kaneshige T, Teraoka H, Akamizu T, Azuma N, Yoshimasa Y, Yoshimasa T, Itoh H, Masuda I, Yasue H, Nakao K. Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension. 1998;32:3-8.
6. Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary disease: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci U S A. 2000;97:2832-2835.
7. Fairchild TA, Fulton D, Fontana JT, Gratton J-P, McCabe TJ, Sessa WC. Acidic hydrolysis as a mechanism for the cleavage of the Glu298→Asp variant of human endothelial nitric-oxide synthase. J Biol Chem. 2001;276:26674-26679.
8. Wang XL, Sim A-H, Badenhop RF, McCredie RM, Wilcken DEL. A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nature Med. 1996;2:41-45.
9. Misko TP, Schilling RJ, Salvemini D, Moore WM, Currie MG. A fluorometric assay for the measurement of nitrite in biological samples. Anal Biochem. 1993;214:11-16.
10. Thorup C, Jones C, Gross SS, Moore LA, Goligorsky MS. Carbon monoxide induces vasodilation and nitric oxide release but suppresses endothelial nitric oxide synthase. Am J Physiol. 1999;277:F882-F889.
11. Brodsky SV, Morrishow AM, Dharia N, Gross SS, Goligorsky MS. Glucose scavenging of nitric oxide. Am J Physiol. 2001;280:F480-F486.
12. Hingorani AD, Liang CF, Fatibene J, Lyon A, Monteith S, Parsons A, Haydock S, Hopper RV, Stephens NG, O'Shaughnessy KM, Brown MJ. A common variant of the endothelial nitric oxide synthase (Glu298→Asp) is a major risk factor for coronary artery disease in the UK. Circulation. 1999;100:1515-1520.
13. Lembo G, DeLuca N, Battagli C, Iovino G, Aretini A, Musicco M, Frati G, Pompeo F, Vecchione C, Trimaro B. A common variant of endothelial nitric oxide synthase (Glu298Asp) is an independent risk factor for carotid atherosclerosis. Stroke. 2001;32:735-740.
14. Yoshimura T, Yoshimura M, Tabata A, Shimasaki Y, Nakayama M, Miyamoto Y, Saito Y, Nakao K, Yasue H, Okamura H. Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with severe preeclampsia. J Soc Gynecol Invest. 2000;7:238-241.
15. Philip I, Plantefeve G, Vuillaumier-Barrot S, Vicaut E, LeMarie C, Henrion D, Poirier O, Levy BI, Desmonts JM, Durand G, Benessiano J. G894T polymorphism in the endothelial nitric oxide synthase gene is associated with an enhanced vascular responsiveness to phenylephrine. Circulation. 1999;99:3096-3098.
16. Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett PH, Knowler WC. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes: Pima Diabetes Gene Group. Diabetes. 1998;47:821-830.
17. Zanchi A, Moczulski DK, Hanna LS, Wantman M, Warram JH, Krolewski AS. Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int. 2000;57:405-413.
18. Neugebauer S, Baba T, Watanabe T. Association of the nitric oxide synthase gene polymorphism with an increased risk for progression to diabetic nephropathy in type 2 diabetes. Diabetes. 2000;49:500-503.
19. Fujita H, Narita T, Meguro H, Ishii T, Hanyu O, Suzuki K, Kamoi K, Ito S. Lack of association between an ecNOS polymorphism and diabetic nephropathy in type 2 diabetic patients with proliferative retinopathy. Horm Metab Res. 2000;32:80-83.
20. Bonnardeaux A, Nandaud S, Charru A, Jeunemaitre X, Corvol P, Soubrier F. Lack of evidence for linkage of the endothelial cell nitric oxide synthase gene to essential hypertension. Circulation. 1995;91:96-102.
21. McMillan MA, Briggs JD, Junor BJ. Outcome of renal replacement treatment in patients with diabetes mellitus. BMJ. 1990;301:540-544.
22. Joki N, Hase H, Ishikawa H, Fukazawa C, Nakamura R, Imamura Y, Tanaka Y, Saijyo T, Fukazawa M, Yamaguchi T. Coronary artery disease as a definitive risk factor of short-term outcome after starting hemodialysis in diabetic renal failure patients. Clin Nephrol. 2001;55:109-114.
23. Iseki K, Fukiyama K. Clinical demographics and long-term prognosis after stroke in patients on chronic haemodialysis. The Okinawa Dialysis Study (OKIDS) Group. Nephrol Dial Transplant. 2000;15:1808-1813.
24. Wattanapitayakul SK, Mihm MJ, Young AP, Bauer JA. Therapeutic implications of human endothelial nitric oxide synthase gene polymorphism. Trends Pharm Sci. 2001;22:361-368.
25. Kaufman RJ. DNA transfection to study translational control in mammalian cells. Methods. 1997;11:361-370.
26. Huang A, Sun D, Smith CJ, Connetta JA, Shesely EG, Koller A, Kaley G. In eNOS knockout mice skeletal muscle arteriolar dilatation to acetylcholine is mediated by EDHF. Am J Physiol. 2000;278:H762-H768.
27. Brandes RP, Schmitz-Winnenthal FH, Feletou M, Godecke A, Huang PL, Vanhoutte PM, Fleming I, Busse R. An endothelial-derived hyperpolarizing factor distinct from NO and prostacyclin is a major endothelium-dependent vasodilator in resistance vessels of wild-type and endothelial NO synthase knockout mice. Proc Natl Acad Sci U S A. 2000;97:9747-9752.
28. Noiri E, Taguchi J, Nakao A, Fujita T. MTHFR gene polymorphism as an exacerbation factor of diabetic nephropathy in type 2 diabetes. Diabetes Care. 2000;23:260. Letter.